Your browser is no longer supported. Please, upgrade your browser.
Rocket Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own0.20% Shs Outstand55.19M Perf Week-3.29%
Market Cap3.52B Forward P/E- EPS next Y-2.14 Insider Trans180.46% Shs Float37.57M Perf Month-5.98%
Income-98.60M PEG- EPS next Q-0.51 Inst Own92.70% Short Float24.57% Perf Quarter88.92%
Sales- P/S- EPS this Y16.70% Inst Trans0.37% Short Ratio13.43 Perf Half Y129.47%
Book/sh4.38 P/B12.57 EPS next Y-10.90% ROA-27.50% Target Price70.50 Perf Year156.64%
Cash/sh3.57 P/C15.40 EPS next 5Y10.80% ROE-35.80% 52W Range9.01 - 63.99 Perf YTD0.38%
Dividend- P/FCF- EPS past 5Y14.60% ROI- 52W High-13.97% Beta1.94
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low510.99% ATR4.77
Employees84 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)54.12 Volatility6.39% 7.54%
OptionableYes Debt/Eq0.28 EPS Q/Q-37.60% Profit Margin- Rel Volume0.85 Prev Close58.37
ShortableYes LT Debt/Eq0.25 EarningsNov 05 BMO Payout- Avg Volume687.16K Price55.05
Recom1.80 SMA20-2.61% SMA5024.33% SMA20097.97% Volume582,272 Change-5.69%
Dec-16-20Initiated UBS Buy $75
Dec-08-20Downgrade Oppenheimer Outperform → Perform
Jul-02-20Initiated JP Morgan Overweight
Jun-25-20Resumed BofA/Merrill Buy $34
Jun-01-20Resumed Oppenheimer Outperform
Nov-06-19Initiated Chardan Capital Markets Buy $30
Sep-26-19Initiated Piper Jaffray Overweight
Apr-23-19Initiated Robert W. Baird Outperform
Mar-15-19Initiated BofA/Merrill Buy $27
Feb-05-19Initiated Oppenheimer Outperform $39
Sep-13-18Initiated Ladenburg Thalmann Buy $30
Jul-10-18Initiated William Blair Outperform
Jan-15-21 08:30PM  
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Dec-18-20 12:10AM  
Dec-14-20 04:01PM  
Dec-10-20 10:52AM  
Dec-09-20 11:32PM  
Dec-08-20 04:00PM  
Dec-07-20 02:30PM  
Dec-06-20 10:00AM  
Dec-02-20 07:00AM  
Nov-24-20 07:00AM  
Nov-13-20 07:00AM  
Nov-04-20 10:37AM  
Oct-16-20 07:15AM  
Oct-13-20 12:04PM  
Oct-01-20 07:00AM  
Sep-24-20 07:00AM  
Sep-04-20 07:00AM  
Sep-02-20 07:00AM  
Aug-27-20 07:00AM  
Aug-26-20 07:00AM  
Aug-05-20 07:00AM  
Jul-13-20 07:00AM  
Jul-08-20 12:53PM  
Jun-29-20 07:00AM  
Jun-27-20 03:16PM  
Jun-08-20 07:00AM  
May-26-20 07:00AM  
May-12-20 07:00AM  
May-10-20 10:39PM  
May-06-20 07:00AM  
May-05-20 07:00AM  
Apr-22-20 07:00AM  
Apr-09-20 08:22AM  
Apr-02-20 09:00AM  
Mar-27-20 10:04AM  
Mar-19-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 07:00AM  
Feb-11-20 09:15AM  
Feb-06-20 07:00AM  
Jan-09-20 09:44AM  
Jan-06-20 12:00PM  
Dec-29-19 03:24AM  
Dec-16-19 07:00AM  
Dec-13-19 04:01PM  
Dec-11-19 07:21AM  
Dec-10-19 10:45PM  
Dec-09-19 07:00AM  
Dec-08-19 06:00PM  
Dec-06-19 07:00AM  
Dec-05-19 07:00AM  
Dec-04-19 09:27AM  
Nov-27-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 09:00AM  
Nov-05-19 07:00AM  
Nov-01-19 11:16AM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-01-19 07:00AM  
Sep-23-19 07:00AM  
Sep-10-19 07:00AM  
Sep-04-19 07:00AM  
Aug-28-19 07:00AM  
Aug-22-19 07:00AM  
Aug-07-19 07:00AM  
Jul-31-19 07:00AM  
Jun-25-19 09:24PM  
Jun-18-19 07:00AM  
May-29-19 10:00AM  
May-23-19 03:00PM  
May-09-19 01:54PM  
May-08-19 07:13AM  
May-07-19 07:00AM  
May-02-19 07:00AM  
Apr-30-19 07:00AM  
Apr-18-19 11:20AM  
Apr-16-19 08:10AM  
Apr-15-19 10:36PM  
Mar-15-19 08:00AM  
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel KinnariChief Operating OfficerDec 28Sale56.7216,761950,74594,977Dec 30 04:50 PM
RTW INVESTMENTS, LPDirectorDec 10Buy56.00247,72013,872,32017,530,044Dec 14 07:19 PM
Shah GauravPresident & CEOMar 24Option Exercise0.4390,92539,0981,061,642Mar 26 07:48 PM
Patel KinnariChief Operating OfficerMar 18Buy9.501,0009,5006,675Mar 19 07:56 PM
Shah GauravPresident & CEOFeb 25Option Exercise0.43290,000125,628976,950Feb 27 05:36 PM